表紙
市場調查報告書

遺傳性血管水腫(HAE)的全球市場:產業分析與預測

Global Hereditary Angioedema Market: Industry Analysis & Outlook 2017-2021

出版商 Koncept Analytics 商品編碼 524954
出版日期 內容資訊 英文 66 Pages
訂單完成後即時交付
價格
遺傳性血管水腫(HAE)的全球市場:產業分析與預測 Global Hereditary Angioedema Market: Industry Analysis & Outlook 2017-2021
出版日期: 2017年06月30日內容資訊: 英文 66 Pages
簡介

本報告提供遺傳性血管水腫(HAE)的全球市場調查,疾病、市場概要,市場整體趨勢,地區市場(美國、歐洲)的詳細情形,市場成長的各種影響要素,競爭情形,主要企業簡介等系統性資訊。

第1章 概要

  • 簡介
  • 症狀
  • 遺傳性血管水腫(HAE)的種類
  • 治療方法

第2章 遺傳性血管水腫(HAE)的全球市場

  • 市場預測(以金額為準)
  • 遺傳性血管水腫的全球市場:各藥品
  • 收益預測:各藥品(以金額為準)
    • Cinryze
    • Haegarda/Berinert

第3章 遺傳性血管水腫(HAE)的地區市場

  • 美國市場
    • HAE的整體患者數
    • HAE預防治療中的患者數
    • HAE的美國市場:各藥品
    • Cinryze的收益預測(以金額為準)
    • Haegarda/Berinert的收益預測(以金額為準)
  • 歐洲市場
    • HAE的整體患者數
    • HAE預防治療中的患者數
    • HAE的歐洲市場:各藥品
    • Cinryze的收益預測(以金額為準)
    • Haegarda/Berinert的收益預測(以金額為準)

第4章 市場動態

  • 推動因素
  • 市場趨勢
  • 課題

第5章 競爭

  • 全球市場
    • 收益和市值比較
    • 治療藥比較

第6章 企業簡介

目錄

Hereditary Angioedema (HAE) is a rare hereditary disease caused by a genetic deficiency in a gene known as C1 inhibitor (C1-INH). It is characterized by attacks of edema (swelling). These are unpredictable and can affect various areas of the body including the stomach, hands, feet, arms, legs, genitals, throat, and face. Depending on the severity of the disease, some people can have many attacks each month, while others go months without an attack.

During an HAE attack, swelling can happen in a variety of places. This includes the hands, feet, genitals, gastrointestinal (GI) tract, and throat. Symptoms last about 2 to 5 days and then slowly decrease. Although people are born with a genetic defect, the symptoms start in childhood and worsen during teenage years. Many people do not know they have HAE until they are diagnosed in adulthood.

There are three types of hereditary angioedema, called type I, II, and III, which can be distinguished by their underlying causes and levels of a protein called C1 inhibitor in the blood. The classification of HAE into 3 types is based on what problem the genetic defect causes. Treatment of HAE relies on long-term prophylaxis, short-term prophylaxis, and the treatment of acute attacks. The long-term goal is to minimize the frequency and severity of angioedema episodes.

The global hereditary angioedema market is set to experience favourable growth driven by factors such as increasing diagnosis of hereditary angioedema & rising health care expenditure. Further, the scope of growth for this market will be broadened by increasing uptake of prophylaxis therapy and global economic development. The major trends that can be observed in this market include introduction of novel drugs, increasing awareness for HAE and oral medication for HAE attacks.

The report “Global Hereditary Angioedema Market: Industry Analysis & Outlook (2017-2021)” analyses the development of this market, with focus on the U.S. and European markets. The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report. The four major players Shire Plc., CSL Limited, Pharming Group N.V. & BioCryst Pharmaceuticals Inc. are being profiled along with their key financials and strategies for growth. The report contains a comprehensive analysis of the global Hereditary Angioedema market along with the study of the regional markets.

Table of Contents

1. Overview

  • 1.1. Introduction
  • 1.2. Symptoms
  • 1.3. Types of HAE
  • 1.4. Treatment Options

2. Global Hereditary Angioedema Market

  • 2.1. Global Hereditary Angioedema Market Forecast by Value
  • 2.2. Global Hereditary Angioedema Market by Drug
  • 2.3. Global Hereditary Angioedema Drug Revenue
    • 2.3.1. Global Cinryze Revenue Forecast by Value
    • 2.3.2. Global Haegarda/Berinert Revenue Forecast by Value

3. Regional Market

  • 3.1. The U.S.
    • 3.1.1. The U.S. Total Hereditary Angioedema & Diagnosed Patients
    • 3.1.2. The U.S. Hereditary Angioedema Patient Population on Prophylaxis
    • 3.1.3. The U.S. Hereditary Angioedema Market by Drug
    • 3.1.4. The U.S. Cinryze Revenue Forecast by Value
    • 3.1.5. The U.S. Haegarda/Berinert Revenue Forecast by Value
  • 3.2. Europe
    • 3.2.1. Europe Total Hereditary Angioedema & Diagnosed Patients
    • 3.2.2. Europe Hereditary Angioedema Patient Population on Prophylaxis
    • 3.2.3. Europe Hereditary Angioedema Market by Drug
    • 3.2.4. Europe Cinryze Revenue Forecast by Value
    • 3.2.5. Europe Haegarda/Berinert Revenue Forecast by Value

4. Market Dynamics

  • 4.1. Growth Drivers
    • 4.1.1. Increasing Diagnosis in the U.S. and Europe
    • 4.1.2. Accelerating Economic Growth
    • 4.1.3. Rising HealthCare Expenditure
    • 4.1.4. Upsurge in Disposable Income
    • 4.1.5. Increase in the Uptake of Prophylaxis Therapy
  • 4.2. Key Trends & Developments
    • 4.2.1. Upcoming Novel Drugs
    • 4.2.2. Increasing Awareness about HAE
    • 4.2.3. Oral Medication for HAE Attacks
  • 4.3. Challenges
    • 4.3.1. Stringent Regulations
    • 4.3.2. High Cost of HAE Drugs
    • 4.3.3. Misdiagnosis of Hereditary Angioedema Disorder
    • 4.3.4. Limitation of Clinical Trials
    • 4.3.5. Side Effects of HAE Drugs

5. Competition

  • 5.1. Global Market
    • 5.1.1. Revenue and Market Cap Comparison
    • 5.1.2. Global Hereditary Angioedema Market - Drug Comparison

6. Company Profiles

  • 6.1. Shire Plc.
    • 6.1.1. Business Overview
    • 6.1.2. Financial Overview
    • 6.1.3. Business Strategies
  • 6.2. CSL Limited
    • 6.2.1. Business Overview
    • 6.2.2. Financial Overview
    • 6.2.3. Business Strategies
  • 6.3. Pharming Group N.V.
    • 6.3.1. Business Overview
    • 6.3.2. Financial Overview
    • 6.3.3. Business Strategies
  • 6.4. BioCryst Pharmaceuticals Inc.
    • 6.4.1. Business Overview
    • 6.4.2. Financial Overview
    • 6.4.3. Business Strategies

List of Charts

  • Hereditary Angioedema Treatment Therapies
  • Global Hereditary Angioedema Market Forecast by Value (2016-2021)
  • Global Hereditary Angioedema Market by Drug (2016)
  • Global Cinryze Revenue Forecast by Value (2016-2021)
  • Global Haegarda/Berinert Revenue Forecast by Value (2016-2021)
  • The U.S. Total Hereditary Angioedema & Diagnosed Patients (2016-2021)
  • The U.S. Hereditary Angioedema Patient Population on Prophylaxis (2016-2021)
  • The U.S. Hereditary Angioedema Market by Drug (2016)
  • The U.S. Cinryze Revenue Forecast by Value (2016-2021)
  • The U.S. Haegarda/Berinert Revenue Forecast by Value (2016-2021)
  • Europe Total Hereditary Angioedema & Diagnosed Patients (2016-2021)
  • Europe Hereditary Angioedema Patient Population on Prophylaxis (2016-2021)
  • Europe Hereditary Angioedema Market by Drug (2016)
  • Europe Cinryze Revenue Forecast by Value (2016-2021)
  • Europe Haegarda/Berinert Revenue Forecast by Value (2016-2021)
  • Increasing Diagnosis in the U.S. and Europe (2016-2021)
  • Global GDP Per Capita (2012-2016)
  • Global HealthCare Expenditure Per Capita (2012-2016)
  • Global GNI Per Capita (2012-2016)
  • Shire Plc. Sales by Therapeutic Areas (2016)
  • Shire Plc. Revenue and Net Income (2012-2016)
  • Shire Plc. Research & Development Expenses (2014-2016)
  • CSL Limited Revenue by Segments (2016)
  • CSL Limited Revenue and Net Profit (2012-2016)
  • CSL Limited Research & Development Expenses (2014-2016)
  • Pharming Group N.V. Revenue by Geographic Region (2016)
  • Pharming Group N.V. Revenue and Net Loss (2012-2016)
  • Pharming Group N.V. Research & Development Expenses (2014-2016)
  • BioCryst Drug Development Programs (2016)
  • BioCryst Pharmaceuticals Inc. Revenue and Net Loss (2012-2016)
  • BioCryst Pharmaceuticals Inc. Research and Development Expenses (2014-2016)

List of Tables

  • Types of Hereditary Angioedema (HAE)
  • Pipeline Drugs in Development for HAE (2016)
  • Global Hereditary Angioedema Key Players - Revenue & Market Cap Comparison (2016)
  • Global Hereditary Angioedema Market - Drug Comparison (2016)
  • Shire Plc. Collaborations and Acquisitions (2016/2017)